Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [11C]AZ14132516
AZ14132516 · 1 trial · 1 indication
Standardized uptake value (SUV) is the radioactivity concentration in given region of interest normalized for injected radioactivity and body weight. Standardised uptake value ratio (SUVR) is the ratio of SUV in a given region of interest to a reference region without significant radioligand uptake
| Arm | Type | Description |
|---|---|---|
| [11C]AZ14132516 | EXPERIMENTAL | Pilot panel: up to 3 participants to complete 1 PET examination each during the course of the study Main panel: up to 6 participants to complete 2 PET examinations each during the course of the study |
| Name | Type | Description |
|---|---|---|
| [11C]AZ14132516 | DRUG | Injection of radioligand for PET examinations |
Inclusion Criteria: Informed Consent 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol. 2. Able and willing to participate in all scheduled evaluations, abide by all study restrictions, and complete a...
Top 15 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 5 | PHASE3 | Duvakitug, balinatunfib, Brivekimig |
| AbbVie, Inc. | ABBV | 16 | PHASE3 | Upadacitinib, Risankizumab, Lutikizumab, Trosunilimab, ABBV-8736 |
| Eli Lilly and Company | LLY | 7 | PHASE3 | Mirikizumab, Tirzepatide, LY4395089, MORF-057 |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 15 | PHASE3 | Vedolizumab, Zasocitinib, Darvadstrocel |
| Johnson & Johnson | JNJ | 24 | PHASE3 | Ustekinumab, Guselkumab, JNJ-78934804, Golimumab, Icotrokinra |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Spyre Therapeutics, Inc | SYRE | 2 | PHASE2 | SPY001, SPY002, SPY003 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Shattuck Labs, Inc. | STTK | 1 | PHASE2 | SL-325 |
| AgomAb Therapeutics NV ADR | AGMB | 2 | PHASE2 | Ontunisertib |
| Hoffmann-La Roche | RHHBY | 1 | PHASE2 | Afimkibart |
| Pfizer Inc. | PFE | 1 | PHASE2 | Etrasimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
AZ14132516 is an investigational small molecule being developed by AstraZeneca PLC under the ticker AZN. It is being studied in Crohn's disease and is currently in Phase 1 clinical development. The compound has also been evaluated as a positron emission tomography tracer in healthy volunteers.
AZ14132516 is being developed as a potential treatment for Crohn's disease, an inflammatory condition of the gastrointestinal tract. It remains investigational and is in Phase 1 development, so it is not approved for any indication. No efficacy results in Crohn's disease have been reported.
AZ14132516 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating the compound, including the early-phase PET imaging study conducted in Sweden.
AZ14132516 is in Phase 1 clinical development. One trial has been completed, an early Phase 1 PET study, and no trials are currently active. The compound is investigational and has not been approved by the FDA or any other regulatory agency for Crohn's disease or any other indication.
AZ14132516 has been evaluated in one completed clinical trial, NCT05818514, titled a PET study to determine biodistribution and binding characteristics of [11C]AZ14132516 in healthy participants. The trial enrolled 8 healthy volunteers in Sweden and was an early Phase 1, uncontrolled study.
Yes, [11C]AZ14132516 is an alternative name for AZ14132516. The bracketed form refers to the carbon-11 radiolabeled version of the compound used as a positron emission tomography tracer in the completed Phase 1 imaging study NCT05818514.